Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Giuliani

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Journal of Neuroinflammation|January 25, 2017
Rab32 connects ER stress to mitochondrial defects in multiple sclerosisYohannes Haile, Xiaodan Deng, Carolina Ortiz-Sandoval, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 14, 2026
Investigations of remibrutinib in models pertinent to multiple sclerosisRajiv W Jain, Atefeh Rayatpour, Kathleen Hagen, et al.
Oncotarget|November 21, 2017
GFAPδ/GFAPα ratio directs astrocytoma gene expression towards a more malignant profileOscar M J A Stassen, Emma J van Bodegraven, Fabrizio Giuliani, et al.
Therapeutic Advances in Neurological Disorders|September 16, 2024
The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristicsJiwon Oh, Nathalie Arbour, Fabrizio Giuliani, et al.
BMC Neurology|October 28, 2021
The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study designJiwon Oh, Nathalie Arbour, Fabrizio Giuliani, et al.
Neuro-Oncology|February 11, 2022
Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse gliomaEmma van Kessel, Sharon Berendsen, Anniek E Baumfalk, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Multiple Sclerosis and Related Disorders|February 13, 2021
Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosisCarlos R Camara-Lemarroy, Claudia Silva, Luanne M Metz, et al.
Journal of Neuroinflammation|January 7, 2022
Anti-inflammatory role of GM1 and other gangliosides on microgliaDanny Galleguillos, Qian Wang, Noam Steinberg, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Siglec-G on B cells restrains the germinal center response by controlling T cell help during positive selectionJhon R Enterina, Sung-Yao Lin, Liany Luna-Dulcey, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of Neuroinflammation|January 25, 2017
Rab32 connects ER stress to mitochondrial defects in multiple sclerosisYohannes Haile, Xiaodan Deng, Carolina Ortiz-Sandoval, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 14, 2026
Investigations of remibrutinib in models pertinent to multiple sclerosisRajiv W Jain, Atefeh Rayatpour, Kathleen Hagen, et al.
Oncotarget|November 21, 2017
GFAPδ/GFAPα ratio directs astrocytoma gene expression towards a more malignant profileOscar M J A Stassen, Emma J van Bodegraven, Fabrizio Giuliani, et al.
Therapeutic Advances in Neurological Disorders|September 16, 2024
The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristicsJiwon Oh, Nathalie Arbour, Fabrizio Giuliani, et al.
BMC Neurology|October 28, 2021
The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study designJiwon Oh, Nathalie Arbour, Fabrizio Giuliani, et al.
Neuro-Oncology|February 11, 2022
Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse gliomaEmma van Kessel, Sharon Berendsen, Anniek E Baumfalk, et al.
Advances in Therapy|November 21, 2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older PatientsYang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, et al.
Multiple Sclerosis and Related Disorders|February 13, 2021
Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosisCarlos R Camara-Lemarroy, Claudia Silva, Luanne M Metz, et al.
Journal of Neuroinflammation|January 7, 2022
Anti-inflammatory role of GM1 and other gangliosides on microgliaDanny Galleguillos, Qian Wang, Noam Steinberg, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Siglec-G on B cells restrains the germinal center response by controlling T cell help during positive selectionJhon R Enterina, Sung-Yao Lin, Liany Luna-Dulcey, et al.
Pageof 6